Inclusion Criteria:  Participation in a prior clinical trial of CM310 for AD(CM310AD001 and CM310AD002) and met one of the following:  Participation in CM310AD001:received study treatment and adequately completed the assessments and completed the EOS(D85±7) visit. Participation in CM310AD002 and met one of the following：i: Received study treatment and adequately completed the assessments and completed the EOS(V12) visit. ii:Treatment termination due to other reasons other than poor compliance or AE related to CM310 , completed the EOS visit . Provide signed informed consent  Exclusion Criteria:  Patients who, during their participation in a previous CM310 clinical trial, developed a SAE/AE deemed related to dupilumab*, which in the opinion of the investigator or of the medical monitor could not suitable to continue the treatment with CM310. Not enough washing-out period for previous therapy. Pregnancy. Other